Impact of Standardized Allergen-Removed Rhus verniciflua Stokes Extract on Advanced Adenocarcinoma of the Ampulla of Vater : A Case Series

Abstract EN

Background.

Adenocarcinoma of the ampulla of Vater (AAV) is a rare malignancy that has a better prognosis than other periampullary cancers.

However, the standard treatment for patients with relapsed or metastatic AAV has not been established.

We investigated the clinical feasibility of standardized allergen-removed Rhus verniciflua stokes (aRVS) extract for advanced or metastatic AAV.

Patients and Methods.

From July 2006 to April 2011, we retrospectively reviewed all patients with advanced AAV treated with aRVS extract alone.

After applying inclusion/exclusion criteria, 12 patients were eligible for the final analysis.

We assessed the progression-free survival (PFS) and overall survival (OS) of these patients during the follow-up period.

Results.

The median aRVS administration period was 147.0 days (range: 72–601 days).

The best tumor responses according to Response Evaluation Criteria in Solid Tumors were as follows: two with complete response, two with stable disease, and eight with progressive disease.

The median OS was 15.1 months (range: 4.9–25.1 months), and the median PFS was 3.0 months (range: 1.6–11.4 months).

Adverse reactions to the aRVS treatment were mostly mild and self-limiting.

Conclusions.

Prolonged survival was observed in patients with advanced AAV under the treatment of standardized aRVS extract without significant adverse effects.